The Influence of Hepatic Function on Prostate Cancer Outcomes After Radical Prostatectomy

Overview

Journal Prostate Cancer Prostatic Dis

Specialties Oncology
Urology

Date 2010 Mar 3

PMID 20195294

Citations 13

Authors

L L Banez

R M Loftis

S J Freedland

J C Presti Jr

W J Aronson

C L Amling

C J Kane

M K Terris

Affiliations

Soon will be listed here.

Abstract

Prostate growth is dependent on circulating androgens, which can be influenced by hepatic function. Liver disease has been suggested to influence prostate cancer (CaP) incidence. However, the effect of hepatic function on CaP outcomes has not been investigated. A total of 1181 patients who underwent radical prostatectomy (RP) between 1988 and 2008 at four Veterans Affairs hospitals that comprise the Shared Equal Access Regional Cancer Hospital database and had available liver function test (LFT) data were included in the study. Independent associations of LFTs with unfavorable pathological features and biochemical recurrence were determined using logistic and Cox regression analyses. Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) levels were elevated in 8.2 and 4.4% of patients, respectively. After controlling for CaP features, logistic regression revealed a significant association between SGOT levels and pathological Gleason sum > or =7(4+3) cancer (odds ratio=2.12; 95% confidence interval=1.11-4.05; P=0.02). Mild hepatic dysfunction was significantly associated with adverse CaP grade, but was not significantly associated with other adverse pathological features or biochemical recurrence in a cohort of men undergoing RP. The effect of moderate-to-severe liver disease on disease outcomes in CaP patients managed non-surgically remains to be investigated.

Citing Articles

Liver Fibrosis Scores and Prostate Cancer Risk and Mortality in the Atherosclerosis Risk in Communities Study.

Wang A, Lazo M, Lu J, Couper D, Prizment A, Vitolins M Cancer Prev Res (Phila). 2023; 16(9):523-530.

PMID: 37339266 PMC: 10527661. DOI: 10.1158/1940-6207.CAPR-23-0168.

Genetically Predicted Circulating Concentrations of Alanine and Alanine Aminotransferase Were Associated with Prostate Cancer Risk.

Yang S, Song J, Yang H, Liu W, Jiang Y, Sun X Clin Epidemiol. 2022; 14:1255-1264.

PMID: 36330075 PMC: 9624164. DOI: 10.2147/CLEP.S382116.

The relationship between lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study.

Ioannidou A, Watts E, Perez-Cornago A, Platz E, Mills I, Key T PLoS Med. 2022; 19(1):e1003859.

PMID: 35085228 PMC: 8794090. DOI: 10.1371/journal.pmed.1003859.

AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer.

Zhou J, He Z, Ma S, Liu R Cancer Med. 2020; 9(15):5672-5677.

PMID: 32562455 PMC: 7402847. DOI: 10.1002/cam4.3086.

Clinical significance of the De Ritis ratio for detecting prostate cancer in a repeat prostate biopsy.

Ha H, Chung J, Ha Y, Choi S, Lee J, Kim B Investig Clin Urol. 2019; 60(6):447-453.

PMID: 31692969 PMC: 6821984. DOI: 10.4111/icu.2019.60.6.447.

References

Banez L, Hamilton R, Partin A, Vollmer R, Sun L, Rodriguez C . Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007; 298(19):2275-80. DOI: 10.1001/jama.298.19.2275. View

Sesso H, Paffenbarger Jr R, Lee I . Alcohol consumption and risk of prostate cancer: The Harvard Alumni Health Study. Int J Epidemiol. 2001; 30(4):749-55. DOI: 10.1093/ije/30.4.749. View

Barba M, McCann S, Schunemann H, Stranges S, Fuhrman B, De Placido S . Lifetime total and beverage specific--alcohol intake and prostate cancer risk: a case-control study. Nutr J. 2004; 3:23. PMC: 543574. DOI: 10.1186/1475-2891-3-23. View

Albertsen K, Gronbaek M . Does amount or type of alcohol influence the risk of prostate cancer?. Prostate. 2002; 52(4):297-304. DOI: 10.1002/pros.10120. View

Dennis L . Meta-analysis for combining relative risks of alcohol consumption and prostate cancer. Prostate. 1999; 42(1):56-66. DOI: 10.1002/(sici)1097-0045(20000101)42:1<56::aid-pros7>3.0.co;2-p. View

Lucia M, Epstein J, Goodman P, Darke A, Reuter V, Civantos F . Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007; 99(18):1375-83. DOI: 10.1093/jnci/djm117. View

Severi G, Morris H, MacInnis R, English D, Tilley W, Hopper J . Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006; 15(1):86-91. DOI: 10.1158/1055-9965.EPI-05-0633. View

Pugh R, Murray-Lyon I, Dawson J, Pietroni M, Williams R . Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60(8):646-9. DOI: 10.1002/bjs.1800600817. View

Lindholm J, Bahnsen M, Boiesen P, Hagen C, Christensen T . Sex steroids and sex-hormone binding globulin in males with chronic alcoholism. Eur J Clin Invest. 1978; 8(5):273-6. DOI: 10.1111/j.1365-2362.1978.tb00841.x. View

10.

Kubota Y, Sasagawa I, Sinzawa H, Kunii T, Itoh K, Miura H . Serum levels of free and total prostate-specific antigen in males with liver cirrhosis. Eur Urol. 1999; 36(5):409-12. DOI: 10.1159/000020022. View

11.

Velicer C, Kristal A, White E . Alcohol use and the risk of prostate cancer: results from the VITAL cohort study. Nutr Cancer. 2006; 56(1):50-6. DOI: 10.1207/s15327914nc5601_7. View

12.

Akdogan M, Hassoun B, Gurakar A, El-Sahwi K, Jazzar A, Wright H . Prostate-specific antigen levels among cirrhotic patients. Int J Biol Markers. 2002; 17(3):161-4. DOI: 10.1177/172460080201700303. View

13.

Breslow R, Weed D . Review of epidemiologic studies of alcohol and prostate cancer: 1971-1996. Nutr Cancer. 1998; 30(1):1-13. DOI: 10.1080/01635589809514633. View

14.

Freedland S, Platz E, Presti Jr J, Aronson W, Amling C, Kane C . Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006; 175(2):500-4. DOI: 10.1016/S0022-5347(05)00162-X. View

15.

Platz E, Leitzmann M, Rimm E, Willett W, Giovannucci E . Alcohol intake, drinking patterns, and risk of prostate cancer in a large prospective cohort study. Am J Epidemiol. 2004; 159(5):444-53. DOI: 10.1093/aje/kwh062. View

16.

Maruyama Y, Adachi Y, Aoki N, Suzuki Y, Shinohara H, Yamamoto T . Mechanism of feminization in male patients with non-alcoholic liver cirrhosis: role of sex hormone-binding globulin. Gastroenterol Jpn. 1991; 26(4):435-9. DOI: 10.1007/BF02782811. View

17.

Presti Jr J, Lee U, Brooks J, Terris M . Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population. J Urol. 2004; 171(6 Pt 1):2199-202. DOI: 10.1097/01.ju.0000124847.82541.60. View

18.

Cetinkaya M, Cetinkaya H, ULUSOY E, Baz S, Memis A, Yasa H . Effect of postnecrotic and alcoholic hepatic cirrhosis on development of benign prostatic hyperplasia. Prostate. 1998; 36(2):80-4. DOI: 10.1002/(sici)1097-0045(19980701)36:2<80::aid-pros2>3.0.co;2-i. View

19.

Thompson I, Goodman P, Tangen C, Lucia M, Miller G, Ford L . The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349(3):215-24. DOI: 10.1056/NEJMoa030660. View

20.

Luppa P, Thaler M, Schulte-Frohlinde E, Schreiegg A, Huber U, Metzger J . Unchanged androgen-binding properties of sex hormone-binding globulin in male patients with liver cirrhosis. Clin Chem Lab Med. 2006; 44(8):967-73. DOI: 10.1515/CCLM.2006.186. View